Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H29ClN8O2 |
InChIKeyURUPFUYPXLMTMT-KPZWWZAWSA-N |
CAS Registry2055938-05-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 28 Jan 2019 | |
| Neoplasms | Preclinical | United States | 28 Jan 2019 |





